One of our goals at Pyrexar Medical is to connect and share all of the great advancements in hyperthermia from around the world. We believe that access to information, sharing of data and participating in a global effort can give access to hyperthermia to more people.
We have started a new section on our website called Opinion Leaders. The purpose of this section is to initiate conversation and make new connections among physicians and researchers currently in the field. We want to create a community for those centers who want to add hyperthermia to their standard of care. We also believe this may give researchers an accelerated path to clinical studies by offering a larger patient database.
Current hyperthermia-focused conferences are in place but often lack the critical mass to expand hyperthermia centers in a meaningful way. There also lacks the global data sharing necessary to move phase III studies forward. For example, the Hyperthermia European Adjuvant Trial (HEAT) is a randomized clinical phase III study comparing chemotherapy vs chemotherapy plus hyperthermia in the treatment of pancreatic cancer. Initiated in 2012 and with an estimated enrollment of 336 participants, the study hopes to fully populate sometime this year. Seven years to generate a viable population study and another two years of data analysis. Could future studies move more rapidly if we had a global collaboration?
We hope we can advance this concept in the near future. Today, we want you to meet Dr. Nagraj Huilgol, our first entry in our Opinion Leaders directory.